Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.37 |
| ▸ | RXRA | P19793 | 5/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16533109 | 0.86 | TRPA1 (0.39) | NFE2L2ACHECYP1A2CYP2A6TRPA1 | |
| SCHEMBL19121837 | 0.86 | TRPA1 (0.39) | NFE2L2ACHECYP1A2CYP2A6TRPA1 | |
| SCHEMBL8981744 | 0.83 | TRPA1 (0.40) | NFE2L2ACHECYP1A2CYP2A6TRPA1 | |
| SCHEMBL84060 | 0.83 | TRPA1 (0.50) | NFE2L2ACHECYP1A2CYP2A6TRPA1 | |
| SCHEMBL18487981 | 0.82 | CHRM1 (0.36) | NFE2L2ACHECYP1A2CYP2A6TRPA1 | |
| SCHEMBL21900429 | 0.81 | TRPA1 (0.39) | NFE2L2ACHECYP1A2CYP2A6TRPA1 | |
| SCHEMBL18078259 | 0.80 | MAOA (0.43) | ACHECYP1A2CYP2A6TRPA1LMNA | |
| SCHEMBL10153933 | 0.80 | ALDH1A1 (0.42) | ACHECYP1A2CYP2A6TRPA1LMNA | |
| SCHEMBL10155650 | 0.79 | PDE2A (0.44) | NFE2L2ACHECYP1A2CYP2A6TRPA1 | |
| SCHEMBL8251516 | 0.79 | TRPA1 (0.42) | NFE2L2ACHECYP1A2CYP2A6TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239768-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| EP-3759109-B1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AS HBV REPLICATION INHIBITORS | GILEAD SCIENCES INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| US-11530210-B2 | Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-12-20 | — | — | US | disclosed |
| US-20210147429-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210017169-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-21 | — | — | US | disclosed |
| WO-2020249799-A1 | PYRIDINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | disclosed |
| US-20200392154-A1 | PYRIDINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | US | disclosed |
| US-8188073-B2 | Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20110251185-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | IIJIMA TORU | 2011-10-13 | — | — | US | disclosed |
| US-20110251185-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | IIJIMA TORU | 2011-10-13 | — | — | US | disclosed |
| US-7998956-B2 | Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7998956-B2 | Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1847533-A1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2007-10-24 | — | — | EP | disclosed |
| WO-2007089034-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007087488-A2 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147429-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | NFE2L2 1666/4885ACHE 4551/4885CYP1A2 1075/4885 |
| US-20210017169-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | NFE2L2 3106/4885ACHE 3737/4885CYP1A2 1174/4885 |
| US-20200392154-A1 | PYRIDINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN1 | NFE2L2 2664/4885ACHE 790/4885CYP1A2 1817/4885 |
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | NFE2L2 2673/4885ACHE 1315/4885CYP1A2 997/4885 |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | NFE2L2 1666/4885ACHE 4551/4885CYP1A2 1075/4885 |
| US-11530210-B2 | Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | NFE2L2 3106/4885ACHE 3737/4885CYP1A2 1174/4885 |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | NFE2L2 1761/4885ACHE 4527/4885CYP1A2 3133/4885 |
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | NR3C2, MC2R, NR3C1 | NFE2L2 311/4885ACHE 4357/4885CYP1A2 164/4885 |
| US-20110251185-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | NR3C2, MC2R, NR3C1 | NFE2L2 311/4885ACHE 4357/4885CYP1A2 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.